Literature DB >> 7545854

Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1.

G Tachedjian1, D J Hooker, A D Gurusinghe, H Bazmi, N J Deacon, J Mellors, C Birch, J Mills.   

Abstract

Foscarnet is a broad-spectrum viral DNA polymerase inhibitor active in vitro and in vivo against human immunodeficiency virus type 1 (HIV-1). Strains of HIV-1 resistant to foscarnet were selected by in vitro passage in increasing concentrations of drug. Reduced susceptibility to foscarnet was evident at the levels of both HIV-1 replication and reverse transcriptase. Biologically cloned, foscarnet-resistant strains with distinct genotypes were hypersensitive to zidovudine, azidodeoxyuridine, nevirapine, and R82913 but had unchanged susceptibility to zalcitibine and didanosine. The reverse transcriptase of foscarnet-resistant strains had unique substitutions Glu89-Lys, Leu92-Ile, or Ser156-Ala, the third being associated with six polymorphic changes. Introduction of these mutations into wild-type HIV-1 by site-directed mutagenesis confirmed their role in foscarnet resistance. In the three-dimensional structure of the reverse transcriptase enzyme these amino acids are located close to the template strand of the template primer and far away from the putative pyrophosphate binding site, suggesting that the mechanism by which HIV-1 becomes resistant to foscarnet is indirect. Foscarnet resistance is thus likely to be mediated through an altered interaction of the mutant enzyme with the template strand of the template primer which distorts the geometry of the polymerase active site and thereby decreases foscarnet binding.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545854     DOI: 10.1006/viro.1995.1453

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

1.  A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.

Authors:  R A Smith; G J Klarmann; K M Stray; U K von Schwedler; R F Schinazi; B D Preston; T W North
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance.

Authors:  J L Hammond; D L Koontz; H Z Bazmi; J R Beadle; S E Hostetler; G D Kini; K A Aldern; D D Richman; K Y Hostetler; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  The nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitors.

Authors:  Y Kew; H Salomon; L R Olsen; M A Wainberg; V R Prasad
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

4.  The glutamine side chain at position 91 on the β5a-β5b loop of human immunodeficiency virus type 1 reverse transcriptase is required for stabilizing the dNTP binding pocket.

Authors:  Nootan Pandey; Chaturbhuj A Mishra; Dinesh Manvar; Alok K Upadhyay; Tanaji T Talele; Thomas W Comollo; Neerja Kaushik-Basu; Virendra N Pandey
Journal:  Biochemistry       Date:  2011-08-23       Impact factor: 3.162

5.  Formation of a quaternary complex of HIV-1 reverse transcriptase with a nucleotide-competing inhibitor and its ATP enhancer.

Authors:  Maryam Ehteshami; Monique Nijhuis; Jean A Bernatchez; Christopher J Ablenas; Suzanne McCormick; Dorien de Jong; Dirk Jochmans; Matthias Götte
Journal:  J Biol Chem       Date:  2013-04-18       Impact factor: 5.157

6.  Hypersusceptibility to substrate analogs conferred by mutations in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Robert A Smith; Donovan J Anderson; Bradley D Preston
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

7.  An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine.

Authors:  D J Hooker; G Tachedjian; A E Solomon; A D Gurusinghe; S Land; C Birch; J L Anderson; B M Roy; E Arnold; N J Deacon
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

8.  Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.

Authors:  G Tachedjian; M French; J Mills
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.

Authors:  Antonio J Acosta-Hoyos; Walter A Scott
Journal:  Viruses       Date:  2010-01-28       Impact factor: 5.048

10.  Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Peter R Meyer; Suzanne E Matsuura; Dianna Zonarich; Rahul R Chopra; Eric Pendarvis; Holly Z Bazmi; John W Mellors; Walter A Scott
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.